Dr. Elizabeth Reczek, PhD
Chief Executive Officer
Ms. Reczek is a serial entrepreneur and biotech executive with extensive experience in technological innovation, enterprise strategy development, business development and alliance management, in the context of novel therapeutic, diagnostic and technology programs. She joined the company from Eutropics where she served in a transition role as the head of therapeutics development. Eutropics is a platform technology company involved in developing diagnostic tools to guiding cancer treatment. From 2007 to 2015, Ms. Reczek held positions of increasing seniority at Excelimmune, a biotech company focused on the creation of therapeutics from mixtures of fully human antibodies. In 2013, Ms. Reczek was appointed President and CEO of Excelimmune and served on the Board of Directors. In early 2015, she negotiated an exclusive license of the company’s core antibody expression technology to Catalent Pharma Solutions. From 2010 to 2012, as Director of Research, she oversaw the development of the company’s Antibody Combination Therapeutic (ACT) expression technology and is a named inventor on the patent, awarded in December of 2013. She was involved from initial concept through the successful isolation of antibodies against Staphylococcus aureus from human donors. She is the author of multiple papers in peer reviewed scientific journals and is a co-inventor on a patent describing a novel method for robust and reproducible manufacture of mixtures of recombinant proteins. She joined SeqLL in November of 2015.
Dr. Reczek holds a B.A in Biochemical Sciences from Harvard University and a Ph.D. in Cancer Biology at MIT, followed by a post-doctoral fellowship focused on tumor cell signaling pathways at Brigham and Women’s Hospital and Harvard Medical School.
Daniel Jones
President / Founder / CTO
Mr. Jones has over 12 years of biotech industry experience, including over a decade in single molecule research. While at Helicos BioSciences, his responsibilities included applications development, instrument prototyping and validation, customer support, and bioinformatics, as well as sales and operations. Previously, Mr. Jones worked at U.S. Genomics in the Methods Development group and on development of their Trilogy 2020 Single Molecule Analyzer and Direct miRNA assays. At EXACT Sciences he worked on the ColoGuard assay, a non-invasive, FDA-approved molecular diagnostic for colorectal cancer.
Mr. Jones holds a Bachelors of Science degree from Trinity College and has studied Biotechnology and Bioinformatics at Brandeis University and the University of Massachusetts.
Alberto Correia
Vice President
Mr. Correia joined the company from Harvard Apparatus Regenerative Medicine where he served as Vice President of Sales, Marketing, Manufacturing and Operations. There he set up and managed collaborations with the leading key opinion leaders in the regenerative medicine field. He established and managed the company’s research system manufacturing and support systems. At Cambridge Biomedical, as Vice President of Sales and Operations, he was involved in all aspects of the company including Sales, Marketing, development and the laboratory where he designed and built the new laboratory facility and developed relations with the four largest diagnostic companies in the world to provide revenue. As Vice President of Marketing at VelQuest Corp, a provider of GMP compliance software to the pharmaceutical industry. He has presented over 50 workshops and seminars at international conferences and meetings on various compliance topics including electronic record requirements, data acquisition and Part 11. As Vice President and General Manager at Unisyn Technologies, a contract manufacturer of Pre-clinical, Phase 1 and Phase 2 therapeutics, he designed, built and ran a GMP production plant. A major project completed while head of development was the design of a new line of bioreactors. Prior to Unisyn, Al held several technical and marketing management positions at Zymark Corporation and was a co-founder of Xydex, a sample handling company that was acquired by Genex. He also held positions in the sales and application laboratory at Waters Associates.
Mr. Correia received a Bachelor’s degree in Chemistry from the College of the Holy Cross.
Abhijeet Shinde
Director of Engineering
With over 12 years’ experience in developing biotechnology and medical device instrumentation and bringing products from concept to commercialization. Mr. Shinde has over 7 years of direct experience with single molecule sequencing at Helicos Biosciences. Mr. Shinde led the system integration efforts of the Heliscope. Previously, Mr. Shinde worked in various startups specialized in automated repair systems, smart infusion pumps, and laparoscopic surgical instruments in FDA regulated environment.
Mr. Shinde holds a Master of Science in Mechanical Engineering from Worcester Polytechnic Institute and a Bachelor of Science in Mechanical Engineering from the University of Pune, India.
Lee Dalton
Director of Sales
Lee brings decades of experience in matching the right technical solution with customer needs. Prior to joining SeqLL, Lee has served in positions of increasing responsibility in CMO organizations such as General Electric Healthcare, Unisyn and Abazyme. With CRO organizations such as Cambridge Biomedical he worked directly with biotechnology and biopharmaceutical companies from their initial research projects, through their clinical trials and finally to providing services to commercial products. At Igen, Invitrogen and Life Technology he worked with scientists to provide research products that accelerated research in various areas. Initially he matched his chemistry background with skills in understand how to automate processes at Zymark, a leader supplying laboratory robotics.
Mr. Dalton holds a BSci in chemistry from Framingham University.
